Alumis (ALMS)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ALMS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Alumis's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | — | $24M |
| Net income | -$155M | -$294M | -$243M |
| Free cash flow | -$134M | -$257M | -$370M |
| EPS (diluted) | -$72.08 | -$10.38 | -$2.86 |
| Operating margin | — | — | -1886.9% |
Superinvestors who own ALMS
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Trimmed | $4M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Alumis's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Srinivas Akkaraju Director |
273,290 | $10.63 | $3M |
| Sep 8, 2026 | Srinivas Akkaraju Director |
273,291 | $10.63 | $3M |
| Sep 4, 2026 | Srinivas Akkaraju Director |
220,070 | $11.17 | $2M |
| Jan 9, 2026 | Srinivas Akkaraju |
588,235 | $17.00 | $10M |
| Jan 8, 2026 | Foresite Labs, Llc |
411,764 | $17.00 | $7M |
| Jan 8, 2026 | James B Tananbaum |
411,764 | $17.00 | $7M |
| Jan 8, 2026 | Foresite Capital Management Vi |
411,764 | $17.00 | $7M |
| Dec 5, 2025 | Srinivas Akkaraju |
186,377 | $9.84 | $2M |
| Dec 4, 2025 | Srinivas Akkaraju |
66,027 | $8.18 | $540,101 |
| Dec 3, 2025 | Srinivas Akkaraju |
100,000 | $7.75 | $775,000 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ALMS trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Alumis insiders buying the stock?
10 open-market insider purchases of ALMS in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Alumis?
1 of the superinvestors Investingly tracks hold ALMS in their latest 13F, including Cliff Asness.
Companies like Alumis
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.